Adhik Ramanathan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

  Covid-19 Vaccine stocks – which includes U.S.-listed pharma and biotech companies. The theme is up by about 640% year-to-date versus about 13% for the S&P 500. [Updated 11/11/2020] Why Pfizer’s Vaccine Data Is Good News For Moderna While Pfizer‘s (NYSE: PFE) surprisingly strong initial Covid-19 vaccine efficacy readout likely marks the beginning of the end of the Covid-19 pandemic, it probably doesn’t mean too much for Pfizer stock, given the limited potential profits and challenges with distribution. In fact, we think that the strong data from the vaccine – which is developed...

Last week, there were two positive developments relating to Pfizer (NYSE: PFE) and its German partner BioNTech’s Covid-19 vaccine, and one possible negative development. Firstly, Pfizer says based on internal testing that its vaccine can tolerate warmer temperatures than initially specified, possibly making it easier to handle and distribute. Under current protocol, the vaccine is being stored and transported at ultra-cold temperatures of -80 to -60 degrees Celsius until five days before use, calling for specialized equipment and a longer thawing period. However, the company is now asking ...

Our indicative theme of Cybersecurity Stocks has returned over 150% since the end of 2019, compared to gains of about 21% on the S&P 500 over the same period. The theme is up by about 5% year-to-date.

  Covid-19 Vaccine stocks – which includes U.S.-listed pharma and biotech companies. The theme is up by about 640% year-to-date versus about 13% for the S&P 500. [Updated 11/11/2020] Why Pfizer’s Vaccine Data Is Good News For Moderna While Pfizer‘s (NYSE: PFE) surprisingly strong initial Covid-19 vaccine efficacy readout likely marks the beginning of the end of the Covid-19 pandemic, it probably doesn’t mean too much for Pfizer stock, given the limited potential profits and challenges with distribution. In fact, we think that the strong data from the vaccine – which is developed...

Enphase Revenues have grown from about $286 million in 2017 to about $624 million in 2019, translating into a growth rate of about 48% each year. SolarEdge’s Revenues, which stand at more than double Enphase’s, have grown from about $607 million to about $1,426 million over the same period, a growth rate of about 53% per year. However, over the last 12 months, Enphase saw revenue rise by 42.1% – much higher than the figure of 19% for SolarEdge, as the company gained market share in the microinverter space. Enphase’s operating margin was 15.2% for the most recent twelve-month period, w...